Cargando…
Choosing a Gliptin
The treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over since years. This remains, despite the knowledge that the combination results in a progressive decline in [beta]-cell function and by 3 years up t...
Autores principales: | Gupta, Vishal, Kalra, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193779/ https://www.ncbi.nlm.nih.gov/pubmed/22029001 http://dx.doi.org/10.4103/2230-8210.85583 |
Ejemplares similares
-
What the future holds for gliptins
por: Jindal, Radhika, et al.
Publicado: (2012) -
Gliptins: A New Class of Oral Antidiabetic Agents
por: Seshadri, K. G., et al.
Publicado: (2009) -
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
por: Fisman, Enrique Z., et al.
Publicado: (2015) -
Acute pancreatitis with gliptins: Is it a clinical reality?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2013) -
Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus
por: Gutch, Manish, et al.
Publicado: (2017)